The Biotech Voyager

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities and emerging technologies. From AI-powered antibody discovery...

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities. From gene therapies that transform the liver into drug facto...

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts examine a striking clinical trial result that has generated significant attention in the cell therapy and oncology communities. The discussion centers on a therapeutic approach that has ac...

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Enter code VOYAGER3 for a 3 month discount at labthread.com

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts dive deep into an innovative approach to cancer treatment that combines AI-driven drug discovery with population-level tumor modeling. The conversation explores how computational platforms...

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts explore a revolutionary approach to organ transplantation that could fundamentally transform how we think about tissue rejection and donor compatibility. The discussion centers on an innov...

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they're big news.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Dan Tardiff, Chief Scientific Officer of CAMP4 Therapeutics, joins the show to explain how his company is using antisense oligonucleotides to upregulate gene expression by targeting regulatory RNAs, why haploinsuffi...

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. Rustam Esanov, co-founder and CEO of Reprogram Bio, joins the show to explain how his company is transforming cancer cells into allies rather than attacking them directly, why the convergence of single cell sequenci...

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news.

Welcome to the Biotech Voyager w/ Jeff and Ben. It's the show that covers what's next in biotech.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they become big news.

Welcome to The Biotech Voyager, the show that covers what's next in biotech.

Jack Gugel, co-founder and CEO of Arkana Therapeutics, joins the show to explain how a molecule discovered in Burmese python metabolism could offer an alternative to GLP-1 drugs, why pythons are the perfect model organism for studying extreme metabolic swings, and why he thinks every PhD should end with a company instead of a postdoc application. Arkana spun out of a University of Colorado Boulder...

Welcome to the BioTek Voyager. It's the show that covers what's next in BioTech, mapping the early-stage signals that are going to be a big deal in a couple years.

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they become major news. If you have any questions, drop them below.

Welcome to The Biotech Voyager. It's the show that covers the early-stage biotech space, uncovering the companies that are going to be a big deal in a couple of years.

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech. Drop a question in the chat to be part of the conversation .

Kevin Walton, CEO of Baseimmune, joins Ben and Jeff to break down one of the most underappreciated problems in modern medicine: fibrosis. IPF alone carries a life expectancy of three to five years upon diagnosis, and despite decades of research only three drugs have been approved, none of which halt or reverse the disease. Kevin explains why every previous approach has failed, why fibrosis is a ne...

Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Feel free to leave a comment, and we will get to it as quickly as we can.